去纤维钠功效与作用

Defibrotide is a mixture of sodium salts of single-stranded deoxyoligonucleotides produced from porcine intestinal mucosal genomic DNA through controlled depolymerization. On March 30, 2016, Defibrotide was approved by the US FDA for the treatment of severe hepatic veno-occlusive disease in adults and children after hematopoietic stem cell transplantation (usually complicated by renal and pulmonary function abnormalities). This is the first drug approved by the FDA for the treatment of severe hepatic veno-occlusive disease. Defibrotide also has a certain therapeutic effect on multiple myeloma. Defibrotide has achieved good results in the treatment of multiple myeloma and hepatic veno-occlusive disease caused by chemotherapy and stem cell transplantation, meeting the treatment needs of this rare and fatal disease. The successful development of Defibrotide is good news for many patients.

Defibrotide is the first drug approved by the FDA for the treatment of severe hepatic venular occlusion, a rare and fatal liver disease. The approval was based on a Phase 2 trial of 75 patients, a Phase 3 trial of 102 patients, and an expansion trial of an additional 351 patients. All patients in the trial were diagnosed with hepatic veno-occlusive disease and associated renal or pulmonary dysfunction after HSCT (hematopoietic stem cell transplantation). In the phase 2 trial, 44% of patients survived 100 days after transplantation, compared with 38% in the phase 3 trial and 45% in the expanded trial, and the FDA noted in a report that the expected 100-day survival rate for patients with severe veno-occlusive disease without defibrotide treatment was 21%-31%.

Treatment with Defibrotide will also produce certain side effects or adverse reactions. The most common side effects of this drug include: hypotension/diarrhea/vomiting/nausea/nose bleeding, etc. The incidence rate of grade 3-4 reactions related to defibrotide is 7%, mainly hypotension/pulmonary and gastrointestinal bleeding/abdominal cramps, etc. The side effects of Defibrotide are usually mild, and patients do not need to worry too much. Concomitant use of Defibrotide and a systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding. Discontinue anticoagulants and fibrinolytics before defibrotide treatment, and consider delaying initiation of defibrotide administration until the effects of the anticoagulant have lessened.

The above is the introduction about Defibrotide. If patients have other questions about Defibrotide (such as drug price, purchase, etc.), they can consult the medical companion travel service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.